Lansoprazole Capsule, Delayed Release
Product Images NDC 68001-111

5 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68001-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Lansoprazole Dr Capsules Usp 15mg 90ct Rev 05-17 (Lansoprazole Capsules 15mg 30s)

Lansoprazole Dr Capsules Usp 15mg 90ct Rev 05-17 (Lansoprazole Capsules 15mg 30s)
Lansoprazole 15 mg delayed-release capsules label for oral use, manufactured by BluePoint Laboratories. The label includes the proprietary and generic name, dosage strength, Rx only designation, and a 90 capsule count. It contains instructions for pharmacists and storage information, along with a barcode and manufacturer details from Bachupally, India.*
FDA Label Image

Lansoprazole Dr Capsules Usp 30 mg 30ct (Lansoprazole Capsules 30mg 90s)

Lansoprazole Dr Capsules Usp 30 mg 30ct (Lansoprazole Capsules 30mg 90s)
Label for Lansoprazole delayed-release capsules, USP 30 mg, manufactured by BluePoint Laboratories. The label indicates the product contains 30 capsules and includes instructions to dispense the accompanying Medication Guide. It also contains storage instructions, a barcode, and warnings about bottle seal integrity.*
FDA Label Image

Figure 1 (Image 01)

Figure 1 (Image 01)
A line graph titled 'Mean Severity of Day Heartburn By Study Day For Evaluable Patients' showing mean severity scores on the y-axis (0 to 2.5) and days from start of treatment on the x-axis (-5 to 60). It compares placebo with lansoprazole 15 mg and 30 mg doses, depicting a decline in heartburn severity over time for both lansoprazole doses compared to placebo.*
FDA Label Image

Figure 2 (Image 02)

Figure 2 (Image 02)
A line graph titled 'Mean Severity of Night Heartburn By Study Day For Evaluable Patients' comparing the effects of placebo, lansoprazole 15 mg, and lansoprazole 30 mg over approximately 60 days. The x-axis represents days from the start of treatment, and the y-axis represents mean severity of night heartburn on a scale from 0 to 3, with lower scores indicating less severity. The graph shows trends in symptom severity over time for each group.*
FDA Label Image

Chemical Structure (Structure)

Chemical Structure (Structure)
Chemical structure diagram of lansoprazole, the active ingredient in the drug Lansoprazole capsules. The diagram depicts the molecular arrangement including rings and functional groups characteristic of lansoprazole.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.